* Cross Country Healthcare Inc CCRN.OQ CCRN.O is
expected
to show a fall in quarterly revenue when it reports results on
November 6 for the period ending September 30 2024
* The Boca Raton Florida-based company is expected to
report a
29.9% decrease in revenue to $310.218 million from $442.29
million a year ago, according to the mean estimate from 8
analysts, based on LSEG data.The company's guidance on July 31
2024, for the period ended September 30, was for revenue between
305.00 million and 315.00 million.
* LSEG's mean analyst estimate for Cross Country Healthcare
Inc
is for earnings of 10 cents per share. The company's EPS
guidance on July 31 2024, for the period ended September 30, was
between 0.08 and 0.12
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 5
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Cross
Country
Healthcare Inc is $19.00, above its last closing price
of $11.33.
The company's guidance on July 31 2024 for the period ended
September 30 was for Earnings before Interest, Taxes,
Depreciation and Amortization of between 305 million and 13
million.The company's guidance on July 31 2024 for the period
ended September 30 was for gross profit margin of 21%.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jun. 30 2024 0.14 0.13 0.10 Missed -24.5
Mar. 31 2024 0.17 0.17 0.19 Beat 10.9
Dec. 31 2023 0.27 0.27 0.29 Beat 6.1
Sep. 30 2023 0.41 0.41 0.39 Missed -4.2
Jun. 0.61 0.61 0.69 Beat 13.3
30 2023
Mar. 31 2023 0.75 0.75 0.84 Beat 12.4
Dec. 31 2022 0.89 0.89 1.09 Beat 21.9
Sep. 30 2022 0.96 0.95 1.07 Beat 12.6
This summary was machine generated November 4 at 21:33 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)